KeyMed Biosciences Inc (2162.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG5252B1023
KeyMed Biosciences Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 428.12 m CNY | 721.79 m CNY |
| Gross profit | 447.14 m CNY | 534.46 m CNY |
| EBIT | -663.79 m CNY | -605.48 m CNY |
| Net income | -515.24 m CNY | -526.47 m CNY |
| Diluted EPS – continuing operations | -2.11 CNY | -1.76 CNY |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About KeyMed Biosciences Inc
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study; and CM518D1, an antibody drug conjugate drug in open-label Phase I/II clinical trial. It is also developing CM336, a CMA x CD3 bispecific antibody in an open-label Phase I/II clinical study for the treatment of patients with relapsed or refractory multiple myeloma; CM313 in Phase II clinical study in subjects with primary immune thrombocytopenia; CM383, an Aß protofibrils antibody in Phase Ib clinical study; and CM559, a N3pG Aß antibody in Phase I clinical study. In addition, the company is involved in the development of CM350, a GPC3 x CD3 bispecific antibody in Phase I/II clinical study; CM326, a TSLP antibody; CM355/ICP-B02/PRO-203, a CD20 x CD3 bispecific antibody; and CM369/ICP-B05, an anti-C-C motif chemokine receptor 8 monoclonal antibody. It has an out-licence agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
More stocks
- InnoDisk (5289.TWO)
- Enliven Therapeutics, Inc. (ELVN)
- Alarm.com Holdings, Inc. (ALRM)
- Jones Tech PLC Class A (300684.SZ)
- Jiangsu Boqian New Materials Stock Co Ltd (605376.SS)
- Tasly Pharmaceutical Group Co Ltd (600535.SS)
- Knife River Corp (KNF)
- Remy Cointreau SA (RCO.PA)
- freenet (FNTN.DE)
- Golden Agri-Resources (GARPY)
- Wesdome Gold Mines Ltd (WDO.TO)
- Shanghai Lingang Holdings Co Ltd A (600848.SS)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.